Could a pill help heavy drinkers cut back? new trial tests mavoglurant
NCT ID NCT06136195
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This early-stage study tests whether mavoglurant, a drug taken as a pill, can reduce alcohol cravings and drinking in people who drink heavily. Researchers will give the drug or a placebo to 63 adults with Alcohol Use Disorder and measure how much they drink and crave alcohol. The goal is to see if mavoglurant might help control drinking behavior.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Connecticut Mental Health Center (SAC and SATU)
RECRUITINGNew Haven, Connecticut, 06511, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06512, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mavoglurant
What this could lead to
If it works, this could point toward a new medication to help heavy drinkers control cravings and reduce alcohol consumption.
What could go wrong
This is a very early Phase 1 trial with only 63 people, so results may not apply widely. The drug may not reduce drinking or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.